Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down before the market opened on Wednesday . The stock had previously closed at $79.86, but opened at $71.64. Zealand Pharma A/S shares last traded at $71.64, with a volume of 200 shares.

Analysts Set New Price Targets

ZLDPF has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 15th. Finally, BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Six investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S currently has an average rating of “Strong Buy”.

Zealand Pharma A/S Price Performance

The company has a market cap of $5.09 billion, a price-to-earnings ratio of 5.15 and a beta of 0.72. The company’s 50 day moving average price is $76.65 and its 200 day moving average price is $68.12. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.21. The firm had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. Equities research analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.